PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 62 filers reported holding PRELUDE THERAPEUTICS INC in Q2 2024. The put-call ratio across all filers is 0.25 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,850,253 | -20.1% | 1,010,565 | -0.6% | 0.00% | – |
Q1 2024 | $4,820,576 | +12.1% | 1,016,999 | +1.0% | 0.00% | – |
Q4 2023 | $4,299,275 | +42.9% | 1,006,856 | +3.4% | 0.00% | – |
Q3 2023 | $3,008,442 | -29.8% | 973,606 | +2.2% | 0.00% | – |
Q2 2023 | $4,288,221 | -17.9% | 952,938 | +4.0% | 0.00% | – |
Q1 2023 | $5,221,280 | -3.9% | 916,014 | +1.9% | 0.00% | – |
Q4 2022 | $5,431,856 | -8.6% | 899,314 | +0.0% | 0.00% | – |
Q3 2022 | $5,943,000 | +26.6% | 899,045 | 0.0% | 0.00% | – |
Q2 2022 | $4,693,000 | -15.0% | 899,045 | +12.3% | 0.00% | – |
Q1 2022 | $5,523,000 | -42.5% | 800,498 | +3.8% | 0.00% | – |
Q4 2021 | $9,604,000 | -73.0% | 771,440 | -32.1% | 0.00% | -100.0% |
Q3 2021 | $35,522,000 | +10.2% | 1,136,722 | +0.9% | 0.00% | 0.0% |
Q2 2021 | $32,238,000 | -14.2% | 1,126,047 | +29.8% | 0.00% | 0.0% |
Q1 2021 | $37,585,000 | -20.4% | 867,420 | +31.5% | 0.00% | 0.0% |
Q4 2020 | $47,212,000 | +3381.7% | 659,845 | +1366.3% | 0.00% | – |
Q3 2020 | $1,356,000 | – | 45,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |